Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Advanced Magnetics' Combidex "Approvable" Letter Requests More Efficacy Data

This article was originally published in The Pink Sheet Daily

Executive Summary

The decision follows the Oncologic Drugs Advisory Committee vote that current data do not support approval of the imaging agent for the proposed indication. FDA suggested that the data be "limited to a well-defined population of specific cancer types," the company says.

You may also be interested in...



EUSA Pharma Gains Foothold In U.S. Market With Cytogen Acquisition

Buyout positions U.K. drug maker to take on new licensing deals on both sides of the Atlantic; oncology filing planned within 12 months, EUSA tells the DAILY.

EUSA Pharma Gains Foothold In U.S. Market With Cytogen Acquisition

Buyout positions U.K. drug maker to take on new licensing deals on both sides of the Atlantic; oncology filing planned within 12 months, EUSA tells the DAILY.

Advanced Magnetics To Weigh European Trial Data For Combidex “Approvable” Response

European development partner Guerbet has submitted a marketing application to the EMEA seeking a narrower indication for the molecular imaging agent.

Related Content

Topics

UsernamePublicRestriction

Register

PS061823

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel